Related Experiment Video
Updated: Aug 4, 2025
Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction
Published on: June 7, 2011
Cardiac tissue engineering for myocardial infarction treatment
Paula Gil-Cabrerizo1, Ilaria Scacchetti2, Elisa Garbayo1
1Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, C/Irunlarrea 1, E-31080, Spain; Navarra Institute for Health Research, IdiSNA, Pamplona, C/Irunlarrea 3, E-31008 Pamplona, Spain.
Novel therapies aim to repair heart tissue after myocardial infarction (MI) by combining cellular and acellular treatments with advanced biomaterials. These strategies enhance cardiac function and regeneration, overcoming limitations of current treatments.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Biomaterials Science
Background:
- Myocardial infarction (MI) causes significant global morbidity and mortality, with current treatments only managing ischemia symptoms, not repairing damaged heart tissue.
- Existing therapeutic strategies like cellular therapy, extracellular vesicles, non-coding RNAs, and growth factors show promise for cardiac repair but face challenges in stability and in vivo efficacy.
- Biomaterial-based delivery systems are crucial for overcoming the limitations of these novel therapies for effective cardiac regeneration.
Approach:
- This review synthesizes recent advancements in cellular and acellular therapies for cardiac repair post-MI.
- It highlights the role of biomaterial delivery systems, including microcarriers, nanocarriers, cardiac patches, and injectable hydrogels, in enhancing therapeutic efficacy.
- The review discusses current trends and preclinical successes, with some approaches progressing to clinical trials.
Key Points:
- Novel therapies focus on restoring cardiac function through cardiomyocyte regeneration, angiogenesis, and preventing adverse ventricular remodeling.
- Biomaterial carriers are essential for improving the stability, engraftment, and in vivo performance of therapeutic agents.
- Diverse biomaterial platforms like hydrogels and cardiac patches offer promising avenues for drug and cell delivery.
Conclusions:
- Significant progress has been made in developing advanced therapies for cardiac repair after MI.
- The integration of biologics with sophisticated biomaterial delivery systems is key to clinical translation.
- Further research is needed to address critical aspects for advancing cardiac tissue engineering approaches to clinical application.
